
























REIVINDICACIONES

1. Un compuesto seleccionado de:

No.	Structure	No.	Structure
1		109B	
1A			
1B			
2			
3			
4			
5		113	
6		114A	

No.	Structure	No.	Structure
7		114B	
7A			
7B		116	
8			
9		118A	
10		118B	
11			
11A			

No.	Structure	No.	Structure
11B			
12			
12A			
12B			
13			
14			
15			
16			

No.	Structure	No.	Structure
17			
18			
19			
20			
21		129A	
22		129B	
23			
24		131A	

No.	Structure	No.	Structure
25		131B	
26			
27			
28			
29			
30			
31			
32			
33			

No.	Structure	No.	Structure
34			
35		141A	
36		141B	
37			
38A			
38B			
39			
40			

No.	Structure	No.	Structure
41			
42		147	
43			
43A			
44			
45			
46			
46A			
46B			

No.	Structure	No.	Structure
47			
48		154A	
49		154B	
50			
50A			
	First eluting isomer		
50B			
	Second eluting isomer		
51			

No.	Structure	No.	Structure
52			
53			
55			
56			
58		163	
59		164	
60			
60A			
60B			

No.	Structure	No.	Structure
61			
		169	
		170A	
64		170B	
65			
67A		173	
67B		174	
68A		175	

No.	Structure	No.	Structure
68B		176	
69A			
69B			
70A			
70B			
71A			
71B			
72			

No.	Structure	No.	Structure
		181A	
		181B	
		183A	
78		183B	
79			
		185	
83A			
83B			


No.	Structure	No.	Structure
84		193	
87			
88			
89A			
89B			
90A		200	
90B			
		205	










No.	Structure	No.	Structure
		206	
		207	
		210	
		211	
		212	
101A		214	
101B			
		216	









No.	Structure	No.	Structure
103A			
103B			
104A		220	
104B			
105A			
105B			
		224	
		225	
109A			










O una sal, profármaco, tautómero, estereoisómero o mezcla de estereoisómeros farmacéuticamente aceptables de los mismos.









2. Un compuesto seleccionado de:







































Primer isómero eluyente





















Segundo isómero eluyente















o una sal, profármaco, tautómero, estereoisómero o mezcla de estereoisómeros farmacéuticamente aceptables de los mismos.

3. El compuesto de acuerdo con la reivindicación 2, en donde el compuesto es:



o un estereoisómero o una mezcla de estereoisómeros de los mismos, o una sal farmacéuticamente aceptable de los mismos.

4. Una composición farmacéutica que comprende un compuesto, o un estereoisómero o una mezcla de estereoisómeros, o una sal farmacéuticamente aceptable del mismo, de cualquier reivindicación precedente y un excipiente.

5. Un método *in vitro* para inhibir la proteína quinasa 1 que interactúa con el receptor, que comprende poner en contacto una proteína quinasa 1 que interactúa con el receptor con un compuesto, o un estereoisómero o una mezcla de estereoisómeros, o una sal farmacéuticamente aceptable del mismo, de acuerdo con una cualquiera de las reivindicaciones 1-3 o La composición farmacéutica de la reivindicación 4.